217 related articles for article (PubMed ID: 33248509)
1. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
[TBL] [Abstract][Full Text] [Related]
2. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
Tavakoli M; Malek M
J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
Ginsberg G; Lowe S
Pharmacoeconomics; 2002; 20(6):367-87. PubMed ID: 12052096
[TBL] [Abstract][Full Text] [Related]
4. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.
Ginsberg GM; Lev B
Pharmacoeconomics; 1997 Nov; 12(5):578-84. PubMed ID: 10174324
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness: summary.
Ringel SP
Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S67-9. PubMed ID: 12396813
[No Abstract] [Full Text] [Related]
6. Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study.
Thakore NJ; Lapin BR; Pioro EP;
Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):140-143. PubMed ID: 31450993
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending.
Fiorentino G; Esquinas AM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):315-316. PubMed ID: 29191046
[No Abstract] [Full Text] [Related]
8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
9. Slowing down ALS--is this good or bad?
Munsat TL
Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2 Suppl 1():S19-22. PubMed ID: 11465919
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.
Messori A; Trippoli S; Becagli P; Zaccara G
Pharmacoeconomics; 1999 Aug; 16(2):153-63. PubMed ID: 10539396
[TBL] [Abstract][Full Text] [Related]
11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing a patient's decision regarding riluzole: an early experience.
Rudnicki SA
J Neurol Sci; 1997 Oct; 152 Suppl 1():S80-1. PubMed ID: 9419060
[TBL] [Abstract][Full Text] [Related]
13. ALS/MND and the perspective of health economics.
Gray AM
J Neurol Sci; 1998 Oct; 160 Suppl 1():S2-5. PubMed ID: 9851642
[TBL] [Abstract][Full Text] [Related]
14. Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of riluzole by disease stage.
Tavakoli M
Eur J Health Econ; 2002; 3(3):156-65. PubMed ID: 15609140
[TBL] [Abstract][Full Text] [Related]
15. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
[TBL] [Abstract][Full Text] [Related]
16. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.
Thakore NJ; Lapin BR; Kinzy TG; Pioro EP
Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):483-494. PubMed ID: 30001159
[TBL] [Abstract][Full Text] [Related]
17. Riluzole for the treatment of amyotrophic lateral sclerosis.
Saitoh Y; Takahashi Y
Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
[TBL] [Abstract][Full Text] [Related]
18. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Moore DH
Cochrane Database Syst Rev; 2001; (4):CD001447. PubMed ID: 11687111
[TBL] [Abstract][Full Text] [Related]
19. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Noyes K; Dick AW; Holloway RG;
Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
